Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed (MAPP2)

MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for PTSD (MAPP2), completed their final session in the clinical trial treatment protocol. The clinical trial program for the Breakthrough Therapy has been sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) since 2000 and administered by MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of MAPS, since 2014.